IRCAD is pleased to announce a strategic collaboration with Focal One – EDAP TMS, a prominent French leader in the development of minimally invasive surgical technologies.
EDAP TMS has developed a pioneering solution that utilizes High-Intensity Focused Ultrasound (HIFU) to achieve precise tumor destruction, guided by a sophisticated robotic ultrasound imaging system. This technology has recently reached significant regulatory milestones, including FDA certification for prostate tissue ablation and the CE mark for the treatment of prostate cancer and deep infiltrated endometriosis.
As part of this partnership, a Focal One robotic system will soon be installed at IRCAD’s headquarters. This installation will enable IRCAD’s R&D teams and EDAP engineers to collaborate on two primary research pillars:
- Artificial Intelligence Integration: The development of AI-driven tools designed to automate tumor targeting while ensuring the preservation of surrounding critical anatomical structures.
- Teleablation Protocols: The advancement of remote “teleablation” procedures, leveraging IRCAD’s world-class expertise and platforms dedicated to telesurgery.
This collaboration underscores the vital synergy between industrial innovation and IRCAD’s research ecosystem, reinforcing a shared commitment to defining the future of minimally invasive therapies.